Friday Insights: Geron Corporation, Himax Technologies, Inc., Agios Pharmaceuticals Inc, Tonix Pharmaceuticals Holding Corp.

Geron Corporation (NASDAQ:GERN) shares are up 6.83% to $4.12 in mid-day trading, after its partner, Johnson & Johnson, received notice from the U.S. Food & Drug Administration (FDA) confirming an Orphan Drug Designation of imetelstat as a treatment for of myelofibrosis. All the 3 analysts polled by TipRanks, rate Geron stock a Buy. With a return potential of 38.55%, the stock’s 12-month consensus target price stands at $5.75.

Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) shares are rising 6.82% in mid-day trading to $8.14, adding to their 9% increase this week, after BofA/Merrill Lynch analyst Daniel Heyler upgraded the stock from Underperform to Buy with a price target of $8.50.

Click Here to see the performance of analyst Daniel Heyler.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares are down 12.60% to $107.15 after the company failed to impress the market with the announcements of clinical trial results. Specifically, the company unveiled data from an ongoing Phase 1 study of its leukemia drug AG-221, showing an overall response rate that was lower than the 56 percent reported earlier with fewer patients. Subsequently, Canaccord analyst reiterated a Hold rating on Agios with a $103 price target, in a research report issued today. Out of the 8 analysts polled by TipRanks, 6 rate Agios stock a Hold, while 2 rate the stock a Buy. With a return potential of 8.87%, the stock’s 12-month consensus target price stands at $115.67.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares are up 10.06% to $8.97 in mid-day trading, after Akiva Felt, an analyst at Oppenheimer, initiated a Buy rating on the stock with a price target of $18. Felt wrote, “We believe Tonix is poised to emerge as an attractive play in CNS drug development with three equally compelling opportunities in fibromyalgia (Phase 3), post-traumatic stress disorder (Phase 2) and tension headache (Phase 2).”

Click Here to see the performance of analyst Akiva Felt.





Stay Ahead of Everyone Else

Get The Latest Stock News Alerts